50 research outputs found
Aleukemic mast cell leukemia associated with chronic myelomonocytic leukemia and chronic lymphocytic leukemia
Classical Hodgkin lymphoma arising in a patient with chronic lymphocytic leukemia (Richter syndrome)
Richter transformation with marked plasmacytic differentiation, mimicking plasma cell neoplasm
Spontaneous remission of chemo-immunotherapy related, non-transplant Epstein–Barr virus-associated lymphoproliferative disorder in a patient with chronic lymphocytic leukemia
Unusual Case of Anaplastic Large Cell Lymphoma Presenting as a Breast Mass in a Patient with no History of Breast Implants
Adenocarcinoma is the most common malignant neoplasm involving breast tissue. In contrast to carcinomas, the other types of malignant neoplasms involving the breast are relatively uncommon. One of the examples of this rare entity is lymphoma. Traditionally, non-Hodgkin lymphomas (NHL) involving the breast are divided into primary lymphoma of the breast and systemic lymphoma, although the distinction could be challenging. Most of NHL involving breast tissue have B cell origin; T cell NHL represents less than 20% of all lymphoma cases. Anaplastic large cell lymphomas (ALCL) involving the breast accounts for even lower percentage of cases. Similar to ALCL involving other sites, there are several main types of ALCL identified: primary cutaneous ALCL and systemic ALCL, which is subdivided into ALK positive and ALK negative subtypes. Relatively recently, an additional distinct subtype of ALK-negative ALCL was described, which is associated with textured breast implants and needs to be considered as a differential diagnosis if patient has a history of breast implants. Here, we report a case of ALCL presented as a breast mass without history of breast implant and discuss similar cases published in the literature
From the archives of MD Anderson Cancer Center: BCR-ABL1-like B acute lymphoblastic leukemia with IGH/EPOR fusion
Usefulness of CD11a and CD18 in flow cytometric immunophenotypic analysis for diagnosis of acute promyelocytic leukemia
Acute promyelocytic leukemia (APL) is an aggressive disease that requires prompt diagnosis and therapy. Flow cytometry immunophenotyping can serve as a screening test for APL before the results of cytogenetic or molecular testing for t(15;17)(q22;q21)/PML-RARα are often dimly expressed or absent in APL. We used flow cytometry immunophenotyping with an antibody panel including CD11a and CD18 to assess 36 APL and 33 other AML cases. HLA-DR, CD11a, and CD18 were absent in 81% of APL and 12% of other AML cases (specificity, 88%). By further including combinations of HLA-DR-, CD2+, and either CD11a- or CD18-, we identified 92% of APL cases with 85% specificity. These data compare favorably with the combination of HLA-DR-, CD34-, and CD117+ for APL diagnosis, which had a sensitivity of 64% in this study